PHARM.AS Pharming Group N.V.
Company Analysis
Latest News
🟢 Pharming Group is trading 11% up today after third-quarter revenue topped expectations
Pharming Group is trading at €0.94, up 10.91%, after preliminary third-quarter revenue beat market expectations. - Its October 22 preliminary report showed...
Pharming's Q3 Revenue Beat Sends Shares Surging — But Can a Rare-Disease Biotech Sustain 21% Growth After Quietly Cutting Its Full-Year Outlook?
Shares of Pharming Group jumped nearly 10% today after the Dutch rare-disease biotech disclosed preliminary third-quarter revenue that blew past analyst...
🟢 Pharming Group is trading 10% up after preliminary Q3 revenue exceeded expectations
Pharming Group is trading at €0.94, up 10.02% after preliminary Q3 revenue exceeded market expectations. - On October 22, Pharming Group announced preliminary...
🟢 Pharming Group is trading 5% up today after preliminary Q3 revenue topped market expectations
Pharming Group is trading at €0.90, up 5.34%, after preliminary Q3 revenue exceeded market expectations. - On October 22, the company announced preliminary Q3...
🔴 Pharming Group is trading 5.4% down today amid CEO exit over strategic alignment
Pharming Group is trading 5.4% down at €0.87, with the decline potentially reflecting the CEO’s immediate departure amid disagreement over strategy. - On...
Pharming Group launches Joenja in Japan, first market for younger children
Pharming Group N.V. launched its drug Joenja (leniolisib) commercially in Japan. The treatment targets activated PI3K delta syndrome (APDS) in adult and...
Pharming Group Slashes 2026 Guidance, Weak RUCONEST Sales Drive EPS Cuts
HC Wainwright lowered Pharming Group’s third-quarter 2026 EPS estimate to $0.20. The previous estimate for the period was $0.30. This revision follows...